| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michelle H Gurel, Yi Han, Andrea L Stevens, Aaron Furtado, David Co. Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis. BMC pharmacology & toxicology. vol 18. issue 1. 2017-10-24. PMID:28372573. |
many patients with acromegaly require medical treatment that includes somatostatin analogs (ssas). |
2017-10-24 |
2023-08-13 |
Not clear |
| Philippe J Caron, Stephan Petersenn, Aude Houchard, Caroline Sert, John S Beva. Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study. Clinical endocrinology. vol 86. issue 4. 2017-10-10. PMID:27874199. |
impaired glycaemic control, characteristic of acromegaly, can be exacerbated by treatment with somatostatin analogues (ssas), particularly those with multireceptor activity. |
2017-10-10 |
2023-08-13 |
Not clear |
| Andrea Giustina, Gherardo Mazziotti, Salvatore Cannavò, Roberto Castello, Giorgio Arnaldi, Giovanna Bugari, Renato Cozzi, Diego Ferone, Anna Maria Formenti, Enza Gatti, Silvia Grottoli, Pietro Maffei, Filippo Maffezzoni, Marcella Montini, Massimo Terzolo, Ezio Ghig. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. The Journal of clinical endocrinology and metabolism. vol 102. issue 7. 2017-10-04. PMID:28419317. |
increase in drug frequency or dose is recommended for acromegaly patients with partial response to long-acting somatostatin receptor ligands (srls). |
2017-10-04 |
2023-08-13 |
Not clear |
| Alejandro Ibáñez-Costa, Márta Korbonit. AIP and the somatostatin system in pituitary tumours. The Journal of endocrinology. vol 235. issue 3. 2017-09-28. PMID:28835453. |
classic somatostatin analogues aimed at somatostatin receptor type 2, such as octreotide and lanreotide, represent the mainstay of medical treatment for acromegaly. |
2017-09-28 |
2023-08-13 |
Not clear |
| Federico Gatto, Richard A Feelders, Sanne E Franck, Peter M van Koetsveld, Fadime Dogan, Johan M Kros, Sebastian J C M M Neggers, Aart-Jan van der Lely, Steven W J Lamberts, Diego Ferone, Leo J Hoflan. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas. The Journal of clinical endocrinology and metabolism. vol 102. issue 6. 2017-09-11. PMID:28323931. |
first-generation somatostatin analogs (ssas), such as octreotide (oct), are the first line medical therapy for acromegaly. |
2017-09-11 |
2023-08-13 |
Not clear |
| A Casagrande, M D Bronstein, R S Jallad, J I Mota, A Tabet, J Abucha. Remission of acromegaly after treatment withdrawal in patients controlled by cabergoline alone or in combination with octreotide: results from a multicenter study. Journal of endocrinological investigation. vol 40. issue 5. 2017-08-22. PMID:28012070. |
remission of acromegaly has been reported after somatostatin analogs withdrawal, but not after withdrawal of combination therapy with cabergoline, and only in case reports of patients controlled by cabergoline alone. |
2017-08-22 |
2023-08-13 |
Not clear |
| Jan-Shun Chang, Ham-Min Tseng, Tien-Chun Chan. Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly. Journal of the Formosan Medical Association = Taiwan yi zhi. vol 115. issue 6. 2017-08-21. PMID:27117887. |
the aim of the present study was to evaluate the serial changes of gh and igf-1 in seven patients with naïve, active acromegaly following presurgical treatment of the somatostatin analog pasireotide long-acting release (lar) and octreotide lar. |
2017-08-21 |
2023-08-13 |
Not clear |
| Jan-Shun Chang, Ham-Min Tseng, Tien-Chun Chan. Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly. Journal of the Formosan Medical Association = Taiwan yi zhi. vol 115. issue 6. 2017-08-21. PMID:27117887. |
future large-population studies to investigate the surgical curative rate after presurgical treatment with somatostatin analogs in patients with acromegaly and macroadenomas close to the cavernous sinus are warranted. |
2017-08-21 |
2023-08-13 |
Not clear |
| Renata S Auriemma, Ludovica F S Grasso, Mariano Galdiero, Maurizio Galderisi, Claudia Pivonello, Chiara Simeoli, Maria Cristina De Martino, Rosario Ferrigno, Mariarosaria Negri, Cristina de Angelis, Rosario Pivonello, Annamaria Cola. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine. vol 55. issue 3. 2017-08-17. PMID:27295183. |
effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. |
2017-08-17 |
2023-08-13 |
Not clear |
| Renata S Auriemma, Ludovica F S Grasso, Mariano Galdiero, Maurizio Galderisi, Claudia Pivonello, Chiara Simeoli, Maria Cristina De Martino, Rosario Ferrigno, Mariarosaria Negri, Cristina de Angelis, Rosario Pivonello, Annamaria Cola. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine. vol 55. issue 3. 2017-08-17. PMID:27295183. |
to date, no data are available on the effects of long-term combined treatment with somatostatin analogues (sa) and pegvisomant (peg) on cardiovascular complications in acromegaly. |
2017-08-17 |
2023-08-13 |
Not clear |
| Maria Fleseriu, Elisha Rusch, Eliza B Gee. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine. vol 55. issue 1. 2017-07-28. PMID:27896545. |
pasireotide long-acting release is a somatostatin analog that is indicated for treatment of patients with acromegaly. |
2017-07-28 |
2023-08-13 |
Not clear |
| Marco Losa, Jens Bollersle. Pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly. Endocrine. vol 52. issue 3. 2017-07-13. PMID:26785848. |
pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly. |
2017-07-13 |
2023-08-13 |
Not clear |
| Rosa Maria Paragliola, Salvatore Maria Corsello, Roberto Salvator. Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary. vol 20. issue 1. 2017-07-10. PMID:27778296. |
somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. |
2017-07-10 |
2023-08-13 |
Not clear |
| Nienke R Biermas. New medical therapies on the horizon: oral octreotide. Pituitary. vol 20. issue 1. 2017-07-10. PMID:28091879. |
somatostatin analog treatment is first line medical treatment in patients with acromegaly. |
2017-07-10 |
2023-08-13 |
Not clear |
| Monica R Gadelha, Luiz Eduardo Wildemberg, Marcello D Bronstein, Federico Gatto, Diego Feron. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. vol 20. issue 1. 2017-07-10. PMID:28176162. |
somatostatin receptor ligands in the treatment of acromegaly. |
2017-07-10 |
2023-08-13 |
Not clear |
| Monica R Gadelha, Luiz Eduardo Wildemberg, Marcello D Bronstein, Federico Gatto, Diego Feron. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. vol 20. issue 1. 2017-07-10. PMID:28176162. |
first-generation somatostatin receptors ligands (srl) are the mainstay in the medical treatment of acromegaly, however the percentage of patients controlled with these drugs significantly varies in the different studies. |
2017-07-10 |
2023-08-13 |
Not clear |
| Monica R Gadelha, Luiz Eduardo Wildemberg, Marcello D Bronstein, Federico Gatto, Diego Feron. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. vol 20. issue 1. 2017-07-10. PMID:28176162. |
in this review, we update the physiology of somatostatin and its receptors (sst), the use of srl in the treatment of acromegaly and the factors involved in the response to these drugs. |
2017-07-10 |
2023-08-13 |
Not clear |
| Iulia Potorac, Albert Beckers, Jean-François Bonnevill. T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective. Pituitary. vol 20. issue 1. 2017-07-10. PMID:28197813. |
t2-weighted mri signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective. |
2017-07-10 |
2023-08-13 |
Not clear |
| Jakob Dal, Katrine Lundby Høyer, Steen Bønløkke Pedersen, Nils Erik Magnusson, Peter Bjerring, Jan Frystyk, Niels Møller, Niels Jessen, Jens Otto Lunde Jørgense. Growth Hormone and Insulin Signaling in Acromegaly: Impact of Surgery Versus Somatostatin Analog Treatment. The Journal of clinical endocrinology and metabolism. vol 101. issue 10. 2017-06-30. PMID:27466699. |
growth hormone and insulin signaling in acromegaly: impact of surgery versus somatostatin analog treatment. |
2017-06-30 |
2023-08-13 |
Not clear |
| Jakob Dal, Katrine Lundby Høyer, Steen Bønløkke Pedersen, Nils Erik Magnusson, Peter Bjerring, Jan Frystyk, Niels Møller, Niels Jessen, Jens Otto Lunde Jørgense. Growth Hormone and Insulin Signaling in Acromegaly: Impact of Surgery Versus Somatostatin Analog Treatment. The Journal of clinical endocrinology and metabolism. vol 101. issue 10. 2017-06-30. PMID:27466699. |
somatostatin analogs (sas) used in acromegaly to suppress gh secretion and tumor growth also suppress insulin secretion and may impact gh signaling. |
2017-06-30 |
2023-08-13 |
Not clear |